BIOMAT Database Logo BIOMAT Database Logo

Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. 1994

K Kaushansky, and S Lok, and R D Holly, and V C Broudy, and N Lin, and M C Bailey, and J W Forstrom, and M M Buddle, and P J Oort, and F S Hagen
Division of Hematology, University of Washington School of Medicine, Seattle 98195.

The development of blood cells including expansion of megakaryocyte progenitor cells requires the interplay of marrow stromal cells and polypeptide cytokines. Recently, characterization of c-Mpl, the receptor encoded by the proto-oncogene c-mpl, revealed structural homology with the haematopoietic cytokine receptor family, and its involvement in megakaryocyte development. We report here that the ligand for c-Mpl is relatively lineage specific, works both alone and synergistically with early acting cytokines to support megakaryocyte colony formation, and acts at a late stage of development to increase megakaryocyte size, polyploidization and expression of differentiation markers. In vivo, c-Mpl ligand stimulates platelet production by greatly expanding marrow and splenic megakaryocytes and their progenitors, and by shifting the distribution of megakaryocyte ploidy to higher values. Thus, as c-Mpl ligand has the expected characteristics of the major regulator of megakaryocyte development, we propose that it be termed thrombopoietin.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D008533 Megakaryocytes Very large BONE MARROW CELLS which release mature BLOOD PLATELETS. Megakaryocyte
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D011971 Receptors, Immunologic Cell surface molecules on cells of the immune system that specifically bind surface molecules or messenger molecules and trigger changes in the behavior of cells. Although these receptors were first identified in the immune system, many have important functions elsewhere. Immunologic Receptors,Immunologic Receptor,Immunological Receptors,Receptor, Immunologic,Receptors, Immunological
D001854 Bone Marrow Cells Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells. Bone Marrow Cell,Cell, Bone Marrow,Cells, Bone Marrow,Marrow Cell, Bone,Marrow Cells, Bone
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000090063 Proto-Oncogene Mas A protein that is encoded by the MAS1 gene. It is a receptor for ANGIOTENSIN 1-7 and acts as an antagonist of ANGIOTENSIN-2 TYPE 1 RECEPTOR. C-Mas Protein,II-Proto-Oncogene Proteins, Cellular,Mas Protein,Mas1 Protein,Proto-Oncogene Protein Mas,Proto-Oncogene Proteins C-Mas-1,C Mas Protein,C-Mas-1, Proto-Oncogene Proteins,Cellular II-Proto-Oncogene Proteins,II Proto Oncogene Proteins, Cellular,Mas, Proto-Oncogene,Protein Mas, Proto-Oncogene,Protein, C-Mas,Protein, Mas,Protein, Mas1,Proteins, Cellular II-Proto-Oncogene,Proto Oncogene Mas,Proto Oncogene Proteins C Mas 1

Related Publications

K Kaushansky, and S Lok, and R D Holly, and V C Broudy, and N Lin, and M C Bailey, and J W Forstrom, and M M Buddle, and P J Oort, and F S Hagen
Modulation of megakaryocytopoiesis by thrombopoietin: the c-Mpl ligand.
August 1995, Blood,
K Kaushansky, and S Lok, and R D Holly, and V C Broudy, and N Lin, and M C Bailey, and J W Forstrom, and M M Buddle, and P J Oort, and F S Hagen
[Clinical use of thrombopoietin (c-Mpl Ligand)].
January 1998, Medicinski pregled,
K Kaushansky, and S Lok, and R D Holly, and V C Broudy, and N Lin, and M C Bailey, and J W Forstrom, and M M Buddle, and P J Oort, and F S Hagen
The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl.
March 1995, The Journal of biological chemistry,
K Kaushansky, and S Lok, and R D Holly, and V C Broudy, and N Lin, and M C Bailey, and J W Forstrom, and M M Buddle, and P J Oort, and F S Hagen
Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin.
December 1995, Blood,
K Kaushansky, and S Lok, and R D Holly, and V C Broudy, and N Lin, and M C Bailey, and J W Forstrom, and M M Buddle, and P J Oort, and F S Hagen
[Thrombopoietin and megakaryocyte differentiation].
October 1998, Schweizerische medizinische Wochenschrift,
K Kaushansky, and S Lok, and R D Holly, and V C Broudy, and N Lin, and M C Bailey, and J W Forstrom, and M M Buddle, and P J Oort, and F S Hagen
Thrombopoietin induces megakaryocyte differentiation in hematopoietic progenitor FDC-P2 cells.
August 1995, The Journal of biological chemistry,
K Kaushansky, and S Lok, and R D Holly, and V C Broudy, and N Lin, and M C Bailey, and J W Forstrom, and M M Buddle, and P J Oort, and F S Hagen
[Mpl ligand (thrombopoietin) and platelet regulation].
January 1996, Annales pharmaceutiques francaises,
K Kaushansky, and S Lok, and R D Holly, and V C Broudy, and N Lin, and M C Bailey, and J W Forstrom, and M M Buddle, and P J Oort, and F S Hagen
Activity of the ligand for c-mpl, thrombopoietin, in early haemopoiesis.
August 1996, British journal of haematology,
K Kaushansky, and S Lok, and R D Holly, and V C Broudy, and N Lin, and M C Bailey, and J W Forstrom, and M M Buddle, and P J Oort, and F S Hagen
c-mpl, the thrombopoietin receptor.
July 1995, Thrombosis and haemostasis,
K Kaushansky, and S Lok, and R D Holly, and V C Broudy, and N Lin, and M C Bailey, and J W Forstrom, and M M Buddle, and P J Oort, and F S Hagen
Role for C-MPL and its ligand thrombopoietin in early hematopoiesis.
December 1997, Leukemia & lymphoma,
Copied contents to your clipboard!